COLUMBIA-ADARC-CORNELL AIDS CLINICAL TRIALS UNIT

描述(改编自应用程序的摘要)：的总体目标 这种应用是在成人艾滋病的临床站点内形成的 临床试验集团(AACTG)，将有效地执行设计的研究 提高对艾滋病的认识和治疗水平。这个网站，一个 哥伦比亚长老会医疗中心(哥伦比亚)与Aaron的联系 钻石艾滋病研究中心(ADARC)将被指定为哥伦比亚-ADARC 艾滋病临床试验股。哥伦比亚大学将作为主要单位，亚洲区域研究中心将作为 这两个机构的合作中的子单位已经科学地 由最近授予的艾滋病研究中心(CFAR)赠款链接。这个 意图是将广泛和互补的临床试验和 基本调查专门知识，以便利执行专家组的 科学议程。哥伦比亚-ADARC单位可能拥有必要的元素 成功地实施了一系列不同的致病和 在人口结构多样化的人群中进行战略性临床试验。 本申请的具体目的是：(1)建立临床试验 有能力进行研究，以提高对 HIV的发病机制和治疗。具体地说，这个单位将致力于 通过对议定书的积极应计，进一步推动委员会的研究议程 本集团科学委员会主办；(二)招聘、留用 AACTG试验中艾滋病毒感染者的不同群体反映了 曼哈顿受影响人口，特别是曼哈顿北部地区 它已经受到艾滋病毒疫情的严重影响，而且 代表着疫情向市中心的渗透。这 将通过从大型初级保健中心招募患者来实现 基础和广泛的区域转介网络；以及(3)促进集团的 通过积极参与AACTG议定书和委员会的科学使命 由哥伦比亚-ADARC调查人员提供。这将包括共享新的 增强患者监护复杂性的技术，从而 生成新的假设，以在AACTG试验的背景下进行测试。因此， 哥伦比亚-ADARC ACTU将积极参与该集团的使命 改善艾滋病毒感染者的健康状况，制定治疗标准 感染艾滋病毒的人。

DESCRIPTION (adapted from the application's abstract): The overall goal of this application is the formation of a clinical site within the Adult AIDS Clinical Trials Group (AACTG) which will effectively execute studies designed to improve the understanding and treatment of HIV disease. This site, a linkage of the Columbia Presbyterian Medical Center (Columbia) with the Aaron Diamond AIDS Research Center (ADARC) will be designated the Columbia-ADARC AIDS Clinical Trials Unit. Columbia will serve as the main unit and ADARC as the sub-unit in this collaboration of two institutions already scientifically linked by the recently awarded Center for AIDS Research (CFAR) grant. The intent is to bring together extensive and complementary clinical trials and basic investigative expertise to facilitate execution of the Group's scientific agenda. A Columbia-ADARC unit may possess the elements necessary to successfully carry out a diverse array of pathogenetically and strategically based clinical trials in a demographically diverse population. The specific aims of this application are: (1) to establish a clinical trials unit that has the capability to conduct studies which advance the knowledge of HIV pathogenesis and treatment. Specifically, this unit will be dedicated to further the AACTG's research agenda through active accrual to protocols sponsored by the scientific committees of the Group; (2) to recruit and retain a diverse population of HIV infected persons in AACTG trials who reflect the affected population in Manhattan, particularly Northern Manhattan, a region which has been severely affected by the HIV epidemic and one that is representative of the penetrance of the epidemic into the inner cities. This will be achieved through recruitment of patients from a large primary care base and broad regional referral network; and (3) to promote the Group's scientific mission by active participation in AACTG protocols and committees by Columbia-ADARC investigators. This will include sharing of new technologies that enhance the sophistication of patient monitoring and thereby generate new hypotheses to test in the context of AACTG trials. Thus, the Columbia-ADARC ACTU will be an active participant in the Group's mission to improve the health of HIV infected individuals and set standards for treatment of HIV disease.